REMPEX PHARMACEUTICALS
Rempex Pharmaceuticals, Inc. is a San Diego-based pharmaceutical company focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens. The company’s internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibit the molecular mechanisms in bacteria responsible for antibiotic resistance.
REMPEX PHARMACEUTICALS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2011-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.rempexpharma.com
Total Employee:
1001+
Status:
Active
Contact:
8588752851
Email Addresses:
[email protected]
Total Funding:
67.5 M USD
Technology used in webpage:
Nginx Dingfeng Xinhui Baidu Cloud
Similar Organizations
Cantab Biopharmaceuticals
Cantab Biopharmaceuticals engages in the discovery and development of innovative drugs and drug formulations.
Fedora Pharmaceuticals
Fedora Pharmaceuticals engages in the discovery and development of antibiotics for life-threatening microbial drug resistance needs.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Current Advisors List
Current Employees Featured
Founder
Investors List
OrbiMed
OrbiMed investment in Series B - Rempex Pharmaceuticals
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Rempex Pharmaceuticals
Vivo Capital
Vivo Capital investment in Series B - Rempex Pharmaceuticals
Adams Street Partners
Adams Street Partners investment in Series B - Rempex Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series B - Rempex Pharmaceuticals
Official Site Inspections
http://www.rempexpharma.com Semrush global rank: 3.88 M Semrush visits lastest month: 1.18 K
- Host name: 204.11.56.48
- IP address: 204.11.56.48
- Location: British Virgin Islands
- Latitude: 18.5
- Longitude: -64.5
- Timezone: America/Tortola
More informations about "Rempex Pharmaceuticals"
Rempex Pharmaceuticals - Crunchbase Company …
Rempex Pharmaceuticals engages in the discovery and development of antibacterial drugs for antibiotic resistance. View contacts for Rempex Pharmaceuticals to access new leads and connect with decision-makers.See details»
Rempex Pharmaceuticals - PitchBook
Developer of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens.See details»
Rempex Pharmaceuticals - Products, Competitors, Financials, …
Rempex Pharmaceuticals operates as a pharmaceutical company. It focuses on the discovery and development of new antibacterial drugs. The company's main offerings include the …See details»
Rempex Pharmaceuticals, Inc.
Meropenem-vaborbactam is a broad-spectrum carbapenem–beta-lactamase inhibitor combination approved in the United States and Europe to treat patients with complicated urinary tract …See details»
Organization | Rempex Pharmaceuticals
Organization Overview. First Clinical Trial. None First Marketed Drug. 2011 minocycline . First NDA Approval. 2017 vaborbactam . Last Known Activity. 2017 Timeline < Back; View all...See details»
Rempex Pharmaceuticals, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Rempex Pharmaceuticals, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Rempex Pharmaceuticals Inc - Company Profile and News
Rempex Pharmaceuticals, Inc. develops and produces pharmaceuticals. The Company focuses on the discovery and development of antibacterial treatments to meet the growing clinical …See details»
Rempex Pharmaceuticals, Inc. (Rempex Pharmaceuticals, Inc.) - 药 …
Meropenem-vaborbactam is a fixed-dose beta-lactam/beta-lactamase inhibitor with potent in vitro and in vivo activity against Klebsiella pneumoniae carbapenemase (KPC)-producing …See details»
Rempex Pharmaceuticals, Inc.: Drug pipelines, Patents, Clinical …
Jun 13, 2023 · Explore Rempex Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 2 news, and 1 literature.See details»
Rempex Pharmaceuticals - VentureRadar
Website: http://www.rempexpharma.com. Similar Companies: Fractyl Laboratories USA Privately Held Fractyl Laboratories is a private medical technology company based in Lexington, Mass. …See details»
Rempex Pharmaceuticals - Company Profile - Tracxn
Oct 30, 2024 · Rempex Pharmaceuticals focused on the discovery and development of new antibacterial drugs to meet the growing clinical need created by multi-drug resistant bacterial …See details»
The Medicines Company Acquires Rempex Pharmaceuticals
Dec 4, 2013 · PARSIPPANY, NJ and SAN DIEGO, CA -- 12/04/13 -- The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex Pharmaceuticals, Inc., a …See details»
Rempex Pharma Acquired by The Medicines Company
Dec 6, 2013 · VC-backed Rempex Pharmaceuticals, a company focused on the discovery and development of antibacterial drugs, has been acquired by The Medicines Company for $140 …See details»
The Medicines Company Acquires Rempex Pharmaceuticals
Dec 4, 2013 · PARSIPPANY, NJ and SAN DIEGO, CA-- (Marketwired - Dec 4, 2013) - The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex …See details»
The Medicines Company acquires Rempex Pharmaceuticals
Dec 6, 2013 · The Medicines Company has announced its acquisition of Rempex Pharmaceuticals, Inc., a San Diego-based pharmaceutical company developing new …See details»
Medicines Company Acquires Rempex for Up to $474M
Dec 4, 2013 · The Medicines Company said today it acquired Rempex Pharmaceuticals for up to $474 million, creating a combined company that expands the buyer’s pipeline by adding …See details»
The Medicines Company Management Discusses Acquisition of …
We’re delighted this morning to announce that we’ve acquired what we believe is the leading privately held company for Multidrug-resistant Gram-negative Therapeutics. Referring now to …See details»
Rempex obtains $90m BARDA contract for development of gram …
Feb 7, 2014 · The Medicines Company subsidiary Rempex Pharmaceuticals has received a contract worth $90m from the Biomedical Advanced Research and Development Authority …See details»
The Medicines Company Acquires Rempex Pharmaceuticals
Dec 4, 2013 · PARSIPPANY, NJ and SAN DIEGO, CA-- (Marketwired - Dec 4, 2013) - The Medicines Company (NASDAQ: MDCO) today announced that it has acquired Rempex …See details»
The Medicines Company snaps up antibiotics firm Rempex
Dec 4, 2013 · RPX7009 is the first of a novel class of beta-lactamase inhibitors designed by Rempex to inhibit an enzyme called KPC, the primary resistance mechanism to carbapenems.See details»